JP2022533876A - Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 - Google Patents
Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 Download PDFInfo
- Publication number
- JP2022533876A JP2022533876A JP2021551868A JP2021551868A JP2022533876A JP 2022533876 A JP2022533876 A JP 2022533876A JP 2021551868 A JP2021551868 A JP 2021551868A JP 2021551868 A JP2021551868 A JP 2021551868A JP 2022533876 A JP2022533876 A JP 2022533876A
- Authority
- JP
- Japan
- Prior art keywords
- lysozyme
- covid
- food
- novel coronavirus
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 88
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 72
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 229940079593 drug Drugs 0.000 title claims description 21
- 108010014251 Muramidase Proteins 0.000 claims abstract description 133
- 102000016943 Muramidase Human genes 0.000 claims abstract description 133
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 133
- 239000004325 lysozyme Substances 0.000 claims abstract description 133
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 133
- 229960000274 lysozyme Drugs 0.000 claims abstract description 133
- 235000013305 food Nutrition 0.000 claims abstract description 54
- 230000007358 intestinal barrier function Effects 0.000 claims abstract description 13
- 230000003247 decreasing effect Effects 0.000 claims abstract description 9
- 230000004064 dysfunction Effects 0.000 claims abstract description 9
- 210000005027 intestinal barrier Anatomy 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims description 65
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 42
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 40
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 40
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 40
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 40
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 40
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 21
- 239000004615 ingredient Substances 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 8
- 238000003759 clinical diagnosis Methods 0.000 claims description 8
- 238000013270 controlled release Methods 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 8
- -1 delayed release Substances 0.000 claims description 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 7
- 238000011330 nucleic acid test Methods 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 7
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 6
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003677 chloroquine Drugs 0.000 claims description 6
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 6
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 6
- 229950008454 favipiravir Drugs 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 6
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 6
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 229940046732 interleukin inhibitors Drugs 0.000 claims description 6
- 229960004525 lopinavir Drugs 0.000 claims description 6
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 6
- 229960003752 oseltamivir Drugs 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 6
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 6
- 229960000329 ribavirin Drugs 0.000 claims description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 6
- 229960000311 ritonavir Drugs 0.000 claims description 6
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 6
- 230000002618 waking effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 abstract description 14
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 208000000884 Airway Obstruction Diseases 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 230000005779 cell damage Effects 0.000 abstract description 3
- 208000037887 cell injury Diseases 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 3
- 208000000059 Dyspnea Diseases 0.000 abstract description 2
- 206010013975 Dyspnoeas Diseases 0.000 abstract description 2
- 230000003871 intestinal function Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 7
- 239000000890 drug combination Substances 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- YLSUMFQEBHBMQB-OOFFSTKBSA-M potassium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydrox Chemical compound [K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O YLSUMFQEBHBMQB-OOFFSTKBSA-M 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004097 EU approved flavor enhancer Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019264 food flavour enhancer Nutrition 0.000 description 3
- 229940074774 glycyrrhizinate Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 3
- 229960004626 umifenovir Drugs 0.000 description 3
- 206010003757 Atypical pneumonia Diseases 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108090000600 Claudin-1 Proteins 0.000 description 1
- 102000004162 Claudin-1 Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- GBEYOWVXSWBVBN-JEDNCBNOSA-N azane;(2s)-2,6-diaminohexanoic acid Chemical group [NH4+].NCCCC[C@H](N)C([O-])=O GBEYOWVXSWBVBN-JEDNCBNOSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229950008558 ulinastatin Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
Abstract
Description
本発明の有益な効果としては以下になる:
本発明が提供するリゾチーム又はその組み合わせによれば、COVID-19新型コロナウイルスによる細胞損傷を効果的に抑制し、COVID-19新型コロナウイルスによる炎症反応を抑制し、肺病変による気道閉塞や呼気量減少を改善し、腸管バリア機能を改善することができる。COVID-19新型コロナウイルス肺炎患者の高ウイルス負荷量、呼吸困難、腸管機能の低下に良好な治療効果を示す。新型コロナウイルスの感染率を低下させ、新型コロナ肺炎の重症率を低下させることができる。また、リゾチームの極めて高い安全性を考えると、新型コロナウイルス感染のリスクが高い未診断グループの新型コロナ肺炎の予防にも非常に重要な価値がある。
”リゾチーム”:すなわちlysozymeである。本発明のリゾチームは、動物、植物、微生物由来のリゾチームであってもよく、天然のリゾチームの組換え体であってもよい。例えば、卵白リゾチーム、ヒトリゾチーム、組換えヒトリゾチーム、ファージリゾチームなどであってもよい。本発明におけるリゾチームには、その薬用塩、例えば塩酸塩、塩化物、硫酸塩、アミノ酸塩などが含まれる。リゾチームは、生体内に広く存在する内因性酵素としてフレミングにより初めて発見された。リゾチームは、世界中で食品や医薬品としての使用が承認されている。米国では安全に使用できる物質として認定されている。WHO、欧州の数か国、日本及び中国では食品添加物としての使用が認められている。中国、日本、シンガポールなどの国では、その薬用が承認されている。リゾチームは、ヘルペスウイルスに対して強い抗ウイルス力を持つことがわかっている。
中国で2019年新型コロナ肺炎が流行した際、当社は湖北省に2回、リゾチームトローチ剤やリゾチーム腸溶錠などの抗菌薬を含む合計200万人民元以上の医薬品を寄付した。これらの医薬品が新型コロナの流行に対する反撃において積極的な役割を果たしていることが分かった。
アフリカミドリザルの腎臓細胞を用いて、COVID-19新型コロナウイルスに対するリゾチームの効果を調べた。
ウイルス:COVID-19、100TCID50の滴定量を使用。
リゾチームを含む組み合わせのCOVID-19ウイルスによる細胞病変に対する抑制作用、及びCOVID-19ウイルスによる炎症に対する抑制効果を研究した。
慢性閉塞性肺疾患の動物モデリングとしては、煙曝露モデルが定番である。動物が煙を長期間吸入すると、粘液分泌の増加、気道の閉塞、肺機能の低下を起こす。本試験では、このモデリング方法を用いて、リゾチームの気道閉塞への影響を評価した。
リゾチーム、グリシルリジン酸モノアンモニウム、グリシルリジン酸モノカリウム。
体重400~500gの雄のHartleyモルモットを、ブランク群、モデル群、リゾチーム経口投与群(200mg/kg)、リゾチーム吸入投与群(2mg/kg)、リゾチーム+グリシルリジン酸モノアンモニウム吸入投与群(2mg/kg+0.1mg/kg)、リゾチーム+グリシルリジン酸モノカリウム経口投与I群(200mg/kg+20mg/kg)、リゾチーム+グリシルリジン酸モノカリウム経口投与II群(200mg/kg+40mg/kg)に無作為に群分けし、各群8匹とする。
鼻と口のみから吸入させる煙曝露装置を用いて,ブランク群を除く各群の動物を、毎日5本のタバコの煙を40分間で吸入させて,週に5日,12週間続けさせる。
吸入投与用のリゾチームとグリシルリジン酸モノアンモニウムを、それぞれ粒子が10μm以下の粉末に粉砕する。経口投与用のリゾチームとグリシルリジン酸モノカリウムを、それぞれ生理食塩水に溶解する。
投与終了後に、気道抵抗測定と100msの呼気量測定を行った。
動物の気道抵抗と100msの呼気量の測定結果を表4に示す。
Claims (52)
- COVID-19新型コロナ肺炎を予防又は治療する医薬品の調製における、リゾチーム又はリゾチームを含む組み合わせの使用。
- 前記組み合わせはさらに、グリシルリジン酸又はその塩を含む、請求項1に記載の使用。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩は、それぞれ別々の医薬品の中に存在するか、或いは同じ医薬品の中に併存する、請求項2に記載の使用。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項2に記載の使用。
- 前記組み合わせはさらに、COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分も含む、請求項1~4の何れか一項に記載の使用。
- 前記COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分は、インターフェロン、オセルタミビル又はその塩、ロピナビル、リトナビル、ファビピラビル、リバビリン、レムデシビル、クロロキン又はその塩、ヒドロキシクロロキン又はその塩、アルビドール又はその塩、インターロイキン阻害剤、腫瘍壊死因子阻害剤、ヤヌスキナーゼ阻害剤、糖質コルチコイド、プロテアーゼ阻害剤、又は腸内環境調整剤の1つ又は複数から選択される、請求項5に記載の使用。
- 前記組み合わせにおけるリゾチーム及びCOVID-19新型コロナ肺炎を予防又は治療に使用できる他の成分は、それぞれ別々の医薬品の中に存在するか、或いは同じ医薬品の中に併存する、請求項5に記載の使用。
- 前記医薬品の製剤形態は、経口剤、注射剤、吸入剤である、請求項1に記載の使用。
- 前記医薬品の放出形態は、即時放出、遅延放出、持続放出又は制御放出である、請求項1に記載の使用。
- 前記医薬品はさらに、薬学的に適用可能な補助剤を含む、請求項1に記載の使用。
- COVID-19新型コロナ肺炎の予防又は治療を補助する食品の調製における、リゾチーム又はリゾチームを含む組み合わせの使用。
- 前記食品は、保健用食品又は特別医療用食品である、請求項11に記載の使用。
- 前記組み合わせはさらに、グリシルリジン酸又はその塩を含む、請求項11に記載の使用。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩は、それぞれ別々の食品の中に存在するか、或いは同じ食品の中に併存する、請求項13に記載の使用。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項13に記載の使用。
- 前記食品はさらに、食物に適用可能な添加物を含む、請求項11に記載の使用。
- 前記添加物は、防腐剤、着色料、調味料、香料、保存料、酸化防止剤、乳化剤、増粘剤、炭水化物、脂肪、ビタミン、アミノ酸、微量元素、又はタンパク質の1つ又は複数から選択される、請求項16に記載の使用。
- COVID-19新型コロナ肺炎を予防又は治療する医薬品であって、リゾチームを含む、医薬品。
- 前記医薬品はさらに、グリシルリジン酸又はその塩を含む、請求項18に記載の医薬品。
- 前記医薬品におけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項19に記載の医薬品。
- 前記医薬品はさらに、COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分も含む、請求項18又は19に記載の医薬品。
- 前記COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分は、インターフェロン、オセルタミビル及びその塩、ロピナビル、リトナビル、ファビピラビル、リバビリン、レムデシビル、クロロキン及びその塩、ヒドロキシクロロキン及びその塩、アルビドール及びその塩、インターロイキン阻害剤、腫瘍壊死因子阻害剤、ヤヌスキナーゼ阻害剤、糖質コルチコイド、プロテアーゼ阻害剤、又は腸内環境調整剤の1つ又は複数から選択される、請求項21に記載の医薬品。
- 前記医薬品の製剤形態は、経口剤、注射剤、又は吸入剤であってもよい、請求項18に記載の医薬品。
- 前記医薬品の放出形態は、即時放出、遅延放出、持続放出又は制御放出であってもよい、請求項18に記載の医薬品。
- COVID-19新型コロナ肺炎の予防又は治療を補助する食品であって、リゾチームを含む、食品。
- 前記食品はさらに、グリシルリジン酸又はその塩を含む、請求項25に記載の食品。
- 前記食品はさらに、食物に適用可能な添加物を含む、請求項25に記載の食品。
- 前記食品におけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項26に記載の食品。
- 所望の対象者に医薬品を投与することを含むCOVID-19新型コロナ肺炎を予防又は治療する方法であって、前記医薬品が、有効量のリゾチームを含むか、又は前記医薬品が、有効量のリゾチームを含む組み合わせを含む、方法。
- 前記対象者はCOVID-19新型コロナウイルスの核酸検査で陽性を示すか、或いはCOVID-19新型コロナ肺炎と臨床診断されている、請求項29に記載の方法。
- 前記対象者に、さらに気道抵抗の増加、呼気量の減少及び/又は腸管バリア機能障害が存在する、請求項30に記載の方法。
- 前記組み合わせはさらに、グリシルリジン酸又はその塩を含む、請求項29に記載の方法。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩は、それぞれ別々の医薬品の中に存在するか、或いはリゾチームとグリシルリジン酸又はその塩は同じ医薬品の中に併存する、請求項32に記載の方法。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項32に記載の方法。
- 前記組み合わせはさらに、COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分も含む、請求項29又は32に記載の方法。
- 前記COVID-19新型コロナ肺炎を予防又は治療するために使用できる他の成分は、インターフェロン、オセルタミビル及びその塩、ロピナビル、リトナビル、ファビピラビル、リバビリン、レムデシビル、クロロキン及びその塩、ヒドロキシクロロキン及びその塩、アルビドール及びその塩、インターロイキン阻害剤、腫瘍壊死因子阻害剤、ヤヌスキナーゼ阻害剤、糖質コルチコイド、プロテアーゼ阻害剤、又は腸内環境調整剤の1つ又は複数から選択される、請求項35に記載の方法。
- 前記組み合わせにおけるリゾチーム及びCOVID-19新型コロナ肺炎を予防又は治療に使用できる他の成分は、それぞれ別々の医薬品の中に存在するか、或いは同じ医薬品の中に併存する、請求項35に記載の方法。
- 前記医薬品の投与方法は、経口服用、注射、又は吸入である、請求項29に記載の方法。
- 前記医薬品の放出形態は、即時放出、遅延放出、持続放出又は制御放出である、請求項29に記載の方法。
- 前記リゾチームの1日当たりの服用量は、0.5gから20gである、請求項29に記載の方法。
- 前記医薬品の服用回数は、起きている時間の1~24時間ごとに1回であり、好ましくは1時間ごと、2時間ごと、4時間ごと、6時間ごと、8時間ごと、12時間ごと、24時間ごとに1回である、請求項29に記載の方法。
- 所望の対象者に食品を投与することを含むCOVID-19新型コロナ肺炎の予防又は治療を補助する方法であって、前記食品は有効量のリゾチームを含む、又は前記食品は有効量のリゾチームを含む組み合わせを含む、方法。
- 前記食品は、保健用食品又は特別医療用食品である、請求項42に記載の方法。
- 前記対象者は、COVID-19新型コロナウイルスの核酸検査で陽性を示すか、或いはCOVID-19新型コロナ肺炎と臨床診断されている、請求項42に記載の方法。
- 前記対象者に、さらに気道抵抗の増加、呼気量の減少及び/又は腸管バリア機能障害が存在する、請求項44に記載の方法。
- 前記組み合わせはさらに、グリシルリジン酸又はその塩を含む請求項42に記載の方法。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩は、それぞれ別々の食品の中に存在するか、或いはリゾチームとグリシルリジン酸又はその塩は同じ食品の中に併存する、請求項46に記載の方法。
- 前記組み合わせにおけるリゾチームとグリシルリジン酸又はその塩の重量比は、100:1~1:100、好ましくは100:1~2:1、より好ましくは100:1~5:1、さらに好ましくは100:1~10:1である、請求項46に記載の方法。
- 前記食品の投与方法は、経口投与、経鼻投与、注射、又は吸入である、請求項42に記載の方法。
- 前記食品の放出形態は、即時放出、遅延放出、持続放出又は制御放出である、請求項42に記載の方法。
- 前記リゾチームの1日当たりの服用量は、0.5gから20gである、請求項42に記載の方法。
- 前記食品の服用回数は、起きている時間の1~24時間ごとに1回であり、好ましくは1時間ごと、2時間ごと、4時間ごと、6時間ごと、8時間ごと、12時間ごと、24時間ごとに1回である、請求項42に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010341811 | 2020-04-27 | ||
CN202010341811.3 | 2020-04-27 | ||
PCT/CN2020/089422 WO2021217702A1 (zh) | 2020-04-27 | 2020-05-09 | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022533876A true JP2022533876A (ja) | 2022-07-27 |
JP7399976B2 JP7399976B2 (ja) | 2023-12-18 |
Family
ID=77378855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021551868A Active JP7399976B2 (ja) | 2020-04-27 | 2020-05-09 | Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220305092A1 (ja) |
EP (1) | EP3928785A4 (ja) |
JP (1) | JP7399976B2 (ja) |
CN (1) | CN113304253A (ja) |
WO (2) | WO2021217702A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024050817A1 (zh) * | 2022-09-09 | 2024-03-14 | 深圳华大智造科技股份有限公司 | 甘草酸或其衍生物在核酸检测中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001525814A (ja) * | 1997-05-14 | 2001-12-11 | アツィーンデ キミケ リユナイト アンジェリーニ フランセスコ ア チ エッレ ア エッフェ ソシエタ ペル アチオニ | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
CN1548152A (zh) * | 2003-05-20 | 2004-11-24 | 孙明杰 | 溶菌酶对严重急性呼吸道综合症的治疗和预防作用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449822A (zh) * | 2003-05-04 | 2003-10-22 | 长春奇龙生物技术研究所 | 基因重组人溶菌酶针对冠状病毒sars在制药中的新用途 |
CN1579189A (zh) * | 2003-08-06 | 2005-02-16 | 孙明杰 | 含有甘草提取物的口香糖 |
CN1618463A (zh) * | 2003-11-21 | 2005-05-25 | 孙明杰 | 预防和治疗sars的复方制剂 |
CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
WO2019046664A1 (en) * | 2017-08-30 | 2019-03-07 | Applied Biological Laboratories, Inc. | COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS |
CN112135625B (zh) * | 2020-04-27 | 2021-07-06 | 广州新创忆药物临床研究有限公司 | 一种预防或治疗covid-19新冠肺炎的药物及其应用 |
-
2020
- 2020-05-09 EP EP20924983.8A patent/EP3928785A4/en active Pending
- 2020-05-09 US US17/441,885 patent/US20220305092A1/en active Pending
- 2020-05-09 CN CN202110657846.2A patent/CN113304253A/zh active Pending
- 2020-05-09 WO PCT/CN2020/089422 patent/WO2021217702A1/zh unknown
- 2020-05-09 JP JP2021551868A patent/JP7399976B2/ja active Active
- 2020-12-04 WO PCT/CN2020/133898 patent/WO2021218154A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001525814A (ja) * | 1997-05-14 | 2001-12-11 | アツィーンデ キミケ リユナイト アンジェリーニ フランセスコ ア チ エッレ ア エッフェ ソシエタ ペル アチオニ | グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物 |
CN1548152A (zh) * | 2003-05-20 | 2004-11-24 | 孙明杰 | 溶菌酶对严重急性呼吸道综合症的治疗和预防作用 |
Non-Patent Citations (2)
Title |
---|
CHINESE JOURNAL OF VIROLOGY, vol. 36, no. 2, JPN6022039835, March 2020 (2020-03-01), pages 160 - 164, ISSN: 0005034435 * |
INDIAN J MED RES., vol. 151, JPN6022039836, February 2020 (2020-02-01), pages 160 - 171, ISSN: 0005034434 * |
Also Published As
Publication number | Publication date |
---|---|
CN113304253A (zh) | 2021-08-27 |
WO2021217702A1 (zh) | 2021-11-04 |
EP3928785A4 (en) | 2022-05-18 |
US20220305092A1 (en) | 2022-09-29 |
JP7399976B2 (ja) | 2023-12-18 |
WO2021218154A1 (zh) | 2021-11-04 |
EP3928785A1 (en) | 2021-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112135625B (zh) | 一种预防或治疗covid-19新冠肺炎的药物及其应用 | |
RU2685706C2 (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
WO2023165566A1 (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
JP7399976B2 (ja) | Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 | |
EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
RU2738885C1 (ru) | Противо-SARS-CoV-2 вирусное средство Антипровир | |
CN113262215B (zh) | 贝壳杉烷类化合物在制备预防和治疗脓毒症及多器官损伤的药物中的应用 | |
CN112805027B (zh) | 一种抗新冠病毒感染的药物与应用 | |
US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
US20230226136A1 (en) | A synergistic formulation for management of respiratory pathogens including coronaviruses | |
EP4104825A1 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
US20160296574A1 (en) | Ephedra alata extracts and methods of use thereof | |
US20230310467A1 (en) | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | |
WO2023192779A2 (en) | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections | |
Mason | American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019 | |
CN116531491A (zh) | 一种干扰素α1b在制备防治甲型流感病毒感染引发的疾病的药物中的用途 | |
WO2022204431A1 (en) | Prevention and treatment of coronavirus infection | |
EP4142691A1 (en) | Clofazimine composition and method for the treatment or prophylaxis of viral infections | |
US20230414557A1 (en) | New therapy concept for the treatment of corona infections, especially covid-19 infections | |
IL294894A (en) | A peptide for the prevention or treatment of covid-19 | |
JPH07188032A (ja) | インフルエンザ治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210830 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230411 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230817 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230912 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7399976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |